Vol. 2, No. 9 May 1, 2019
Cancer Institute Member Spotlight
Robert Eoff, Ph.D.
Associate Professor
Department of Biochemistry & Molecular Biology
College of Medicine
Biochemistry Track Leader for Graduate Program in Interdisciplinary Biomedical Sciences
|
|
|
|
|
A long-term goal of Dr. Eoff's research program is to uncover new mechanistic features of replication stress and DNA damage tolerance by studying these processes at the atomic, molecular and cellular level using a variety of techniques, including biochemical and biophysical approaches, methods related to cellular and molecular biology, and systems level approaches, such as proteomics. Read more>
|
|
What's in a Name?
As we move forward in our quest for NCI Designation, it is vitally important for us all to present clear and consistent messages to audiences outside of UAMS. This includes the way in which we use the Cancer Institute's name.
While it may be convenient to shorten or abbreviate our name, only certain versions are approved for use with external audiences, including funding organizations, media outlets, academic journals, etc.
The approved uses of our name include:
- UAMS Winthrop P. Rockefeller Cancer Institute
- Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences
- Winthrop P. Rockefeller Cancer Institute at UAMS
- UAMS Cancer Institute (on second reference only)
- Cancer Institute (on second reference only)
Abbreviations such as WPRCI should never be used with external audiences.
Rockefeller Cancer Institute also should not be used. This shortened version of our name is very similar to the Winthrop Rockefeller Institute, located on Petit Jean Mountain, and could easily cause confusion among those unfamiliar with our different institutions.
|
|
|
Research led by Mayumi Nakagawa, M.D., Ph.D., was recently featured on the KATV evening news.
Her team’s work at understanding the science of naturally occurring HPV infection, led to the design of a therapeutic vaccine for treating patients with cervical dysplasia or pre-cancer.
A phase 1 clinical trial that tested the vaccine’s safety was performed from 2013-2015 and was supported by a grant from the NCI. A phase 2 clinical trial testing the effects of the vaccine is now underway and actively recruiting women between the ages of 18-50 who were recently told they have high-grade dysplasia.
|
|
A commentary by Frits van Rhee, M.D., Ph.D., appeared in the April 18, 2019, issue of Blood. van Rhee and co-author Katie Stone
examine a report on treating newly diagnosed idiopathic multicentric Castleman disease patients with a new regimen using a combination of oral thalidomide, cyclophosphamide and prednisone to attack the disease through multiple mechanisms of action.
|
Sharp Malak, M.D., M.P.H., co-authored the article "Relationships Between Health Care Disparities and Coverage Policies for Breast, Colon, and Lung Cancer Screening" that appeared in Vol. 16, Issue 4 of the Journal of the American College of Radiology.
|
|
Send your publications, grants, awards or other resesarch-related accomplishments to Susan Van Dusen, communications manager, to be shared here or through our other communication outlets. Information and photos are welcome.
|
|
Know someone who needs to be added to our email list? Send their name to Susan Van Dusen.
|
|
|
|
|
